Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Arvinas Holding Company ( (ARVN) ).
On June 6, 2025, Arvinas, in collaboration with Pfizer, announced the submission of a New Drug Application to the U.S. FDA for vepdegestrant, aimed at treating patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. This submission follows promising results from the Phase 3 VERITAC-2 clinical trial, which demonstrated the potential of vepdegestrant as a new treatment option, marking a significant step in Arvinas’ efforts to advance cancer therapies and potentially impact the market for breast cancer treatments.
The most recent analyst rating on (ARVN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas’s overall stock score reflects strong revenue growth and positive strategic developments from recent earnings calls, but is weighed down by ongoing profitability challenges and mixed technical indicators. The company’s negative valuation metrics further contribute to a cautious outlook.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas is a clinical-stage biotechnology company based in New Haven, Connecticut, specializing in the development of protein degradation therapies through its PROTAC (PROteolysis Targeting Chimera) platform. The company focuses on creating treatments for debilitating and life-threatening diseases, with investigational drugs targeting conditions such as advanced or metastatic ER+/HER2- breast cancer, non-Hodgkin Lymphoma, and neurodegenerative disorders.
Average Trading Volume: 3,089,836
Technical Sentiment Signal: Sell
Current Market Cap: $507.3M
For an in-depth examination of ARVN stock, go to TipRanks’ Stock Analysis page.